Success Stories: EB-1B Petition Approved for Research Associate in Colorado in the Field of Immunology
Client’s Testimonial:
Thanks for the great message. Thanks for all your works, collaborations and helps. I really appreciate it. I will share my story at mitbbs and absolutely I will recommend you.
We Received EB-1B Approval for a Research Associate in the Field of Immunology on April 29th, 2015 (Approval Notice)
Position at the Time of Case Filing: Research Associate
Petitioner: Medical Institution
Country of Origin: China
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Colorado
Approval Notice Date: April 29th, 2015
Processing Time: 2 Days (Premium Processing Requested)
At North America Immigration Law Group, we recently received an EB-1B approval for a Research Associate in the field of Immunology. The beneficiary’s outstanding ability, highly skilled background, and impressive record of achievement provided a strong case for his EB-1B petition. His specialized immunological research has focused on the proteases and proteins governing natural killer (NK) regulation and their associated functions, as well as several FOXP3-interacting proteins that are critical to regulatory T cell (Treg) functionality and the molecular mechanisms behind human rhinovirus (HRV) infection-related asthma exacerbations. His research work had resulted in 5 peer-reviewed scientific articles. He had also reviewed 10 manuscripts for journals at the time we filed the case. Furthermore, the beneficiary had a total of 195 citations to his work by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. The petitioner in this case was a medical institution. The significance of the beneficiary’s research is confirmed in the following quote by an independent recommender, “[Client] is the first scientist who reported a human-specific protein which is important for Foxp3 function… Regulation of the members of the FOXP3 interactsome offers opportunities for the development of new treatments for autoimmune diseases, cancer or infectious diseases.” It was our goal to prove that this beneficiary qualified for classification as an outstanding professor or researcher given the international recognition for his outstanding achievements. With the proof and documentation that we provided, his case was approved in 2 days.

